Neuronetics stock fell 2.70 percent as Q2 growth emerged

Published on 10/04/2026 at 19:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Neuronetics stock closed at USD 2.16 on October 2 after a 2.70 percent decline. Q2 revenue beat consensus by 3.20 percent, while analysts kept a Moderate Buy view.

STIM, US64131A1051, Illustration mit AI erstellt.

Neuronetics stock (ISIN US64131A1051) closed at USD 2.16 on Nasdaq on October 2, 2026, down 2.70 percent from the prior close of USD 2.22. The latest company report showed Q2 2026 revenue of USD 41.57 million and an adjusted loss of USD 0.05 per share, giving investors two opposing signals: operating improvement and continued losses.

Q2 revenue beats consensus

Zacks reported on August 11, 2026, that Q2 revenue exceeded consensus by 3.20 percent. The USD 0.05 adjusted loss per share compared with a consensus loss of USD 0.11 and a loss of USD 0.15 in Q2 2025.

The result marks a narrower per-share loss on a year-over-year basis, while the company remains dependent on revenue growth to improve profitability. Neuronetics develops the NeuroStar Advanced Therapy System, a noninvasive transcranial magnetic stimulation treatment for psychiatric disorders, according to its investor-relations page.

Analyst targets stay above market

MarketBeat reported on September 11, 2026, that B. Riley Financial began coverage with a Buy rating and a USD 5.00 price target. The same report listed a Moderate Buy consensus and an average target of USD 4.67.

MarketBeat also reported on September 17, 2026, that BTIG Research reiterated a Buy rating with a USD 6.00 target. Its analyst tally showed four Buy ratings and one Sell rating, making the consensus more favorable than the latest share-price action.

Stock remains below yearly high

At USD 2.16 on October 2, 2026, the stock stood USD 1.28 below its 52-week high of USD 3.44 and USD 1.36 above its 52-week low of USD 0.80. Trading volume was 1,266,080 shares, while market capitalization was USD 150.3 million on the same date.

The valuation debate therefore centers on execution. Q2 revenue growth and the smaller adjusted loss support the recovery case, while the negative per-share result keeps profitability as the key operating checkpoint for the next report.

Neuronetics stock trades at USD 2.16

Neuronetics stock closed at USD 2.16 on Nasdaq on October 2, 2026, with a 2.70 percent daily decline and a market capitalization of USD 150.3 million. The company is classified in the Healthcare sector and Medical Devices industry.